CRTSF - Chr. Hansen: Outperformance After The Merger And New Novonesis
2024-06-28 07:57:06 ET
Summary
- Valuation for Novonesis indicates a "Hold" rating with a price target of 400 DKK/share for double-digit upside potential.
- Christian Hansen's coverage ends after the merger with Novozymes, resulting in Novonesis.
- Novonesis is a leading biosolutions partner with significant market share and growth potential.
Dear readers/followers,
This will be the last coverage of the Chr. Hansen Holding A/S ( OTCPK:CRTSF ) ( OTCPK:CHYHY ) ticker after the merger with Novozymes A/S ( OTCPK:NVZMY ). I have been invested in Christian Hansen for a number of years, and have been covering the company with a bullish rating here on SA for some time as well. My latest coverage can be found here in December of 2023. In that article I spoke a bit about the pending merger with Novozymes, and why I believed this to be a value-add for the company and for the shareholders in either.
In the last stand-alone coverage for Christian Hansen, the company recorded strong financial performance with 16% organic revenue growth and double-digit growth in core segments....
Chr. Hansen: Outperformance After The Merger And New Novonesis